Skip to Content

Oto End 10

Generic name: pramoxine hcl, hydrocortisone, chloroxylenol
Dosage form: otic solution
Drug class: Otic steroids with anti-infectives

Medically reviewed by Last updated on June 21, 2021.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Oto End 10 Description

Oto-End 10 Ear Drops is an anti-inflammatory, antimicrobial and local anesthetic solution for use in the external ear only.

Each 1 mL for otic administration contains:

Hydrocortisone . . . . . . . . . . . . . . 10 mg

Pramoxine Hydrochloride . . . . . . 10 mg

Chloroxylenol . . . . . . . . . . . . . . . . 1 mg

Hydrocortisone (cortisol) is an anti-inflammatory and antipruritic agent. It is a white to practically white, odorless, crystalline powder, very slightly soluble in water. It has the chemical name Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-,(11β)- and the following structural:

C 21H 30O 5
M.W. 362.46

Pramoxine hydrochloride is a topical anesthetic. Used as the hydrochloride salt, it has the chemical name Morpholine, 4-[3-(4-butoxyphenoxy)propyl]-, hydrochloride.

C 17H 27NO 3 • HCl
M.W. 329.86

Chloroxylenol (4-chloro-3, 5-dimethyl phenol or meta-chloro-xylenol) is a wide spectrum antimicrobial agent. It has the following structural formula.

C 8H 9ClO
M.W. 156.61


In a non aqueous vehicle containing edetate disodium EDTA, Poloxamer 188, propylene glycol, propylene glycol diacetate, propylgallate, and purified water.

Oto End 10 - Clinical Pharmacology

Pramoxine hydrochloride is a topical anesthetic which is chemically unrelated to procaine and the other “caines”. It provides temporary relief from itching and pain by stabilizing the neuronal membranes of nerve endings with which it comes into contact.

Hydrocortisone is a corticosteroid which has anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory action of topical corticosteroids is unclear. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically- administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Chloroxylenol in low concentrations is a germicide that may be used to treat bacterial and fungal infections. It is a halogenated phenol, nontoxic, non-corrosive, non-staining with a high phenol coefficient. It may be applied directly to a wound and shows no chemical reactivity toward blood.

Indications and Usage for Oto End 10

For the treatment of superficial infections of the external ear caused by microbes, and to control the accompanying inflammation and itching.


Topical corticosteroids are contraindicated in varicella, vaccinia and in patients sensitive to any of the components of this preparation. This medication should not be applied in the external auditory canal where there is a perforated eardrum or when this medication can reach the middle ear.


This product should be used with care in cases of long-standing otitis media because of the possible perforation of the eardrum concomitant with the external ear use of this product. This preparation is not intended for opthalmic or oral use. If irritation or sensitization occurs, promptly discontinue use of this preparation and institute other measures.



Treatment should not be continued for longer than ten days and the source of infection and/or inflammation evaluated to determine whether therapy should be changed. Systemic absorption of topical corticosteroids has produced reversible hypothalmic- pituitary-adrenal (HPA) axis suppression, manifestation of Cushing’s syndrome, hyperglycemia and glycosuria in some patients. Conditions which augment systemic absorption include the application of more potent steroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug.

Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see Pediatric Use section).

Information for Patients:

Patients using topical corticosteroids should receive the following information and instructions:

  • The medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes.
  • Do not use this medication for any disorder other than which it was prescribed.
  • Check with your physician before using this medication for future ear problems.
  • Report any signs of local adverse reactions to your physician.
  • Keep this and all medication out of the reach of children. In case of accidental overdose, seek professional assistance or contact a poison control center immediately.
  • Store at 20°-25°C (68°-77°F); see USP Controlled Room Temperature.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect of topical corticosteroids on fertility. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.


Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients in large amounts or for prolonged periods of time.

Nursing Mothers:

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use:

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid- induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface to body weight ratio. Cushing’s syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids.

Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regime. Chronic corticosteroid therapy may interfere with growth and development of children.

Adverse Reactions

The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, allergic contact dermatitis, skin atrophy, striae, and miliaria.


Topically-applied corticosteroids can be absorbed in sufficient amount to produce systemic effects. Treatment of overdosage should be symptomatic and supportive.

Oto End 10 Dosage and Administration

The external ear, that is the auricle and the auditory canal should be thoroughly cleansed and dried. Four (4) to 5 drops of Oto-End 10 Ear Drops should be instilled into the affected ear 3 or 4 times daily. For infants and small children, 3 drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward to instill the drops and this position maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary for the opposite affected ear. If preferred, a gauze ear plug or a wick may be inserted into the ear canal prior to applying Oto-End 10 Ear Drops. When using a wick, a few drops of sterile water should be applied directly to the wick following insertion to facilitate hydration. It should then be saturated with Oto-End 10 Ear Drops. The patient should be instructed to add a few drops of Oto-End 10 Ear Drops to the wick every four hours, and to remove the wick after 24 hours. Five (5) drops of Oto-End 10 Ear Drops should be instilled 3 or 4 times daily thereafter. When using a gauze ear plug, the external ear canal is first treated with drops of Oto-End 10 Ear Drops. Next, the gauze is inserted into the ear canal to contain the medication. The gauze ear plug or the expanded wick are easily removed using fingers, forceps, or tweezers. This product may be used in the unaffected ear 3 times daily as a preventative.

How is Oto End 10 Supplied

Oto-End 10 Ear Drops is supplied in plastic dropper bottles of 10 mL, NDC 68047-051-10.


Storage and Handling

Store at 20°-25°C (68°- 77°F); see USP Controlled Room Temperature.

Pharmacist: Dispense in this container.

Rx Only

All prescription substitutions using this product shall be pursuant to state statues as applicable. This is not an Orange book product.

Distributed by:

Larken Laboratories, Inc.

Canton, MS 39046

500339 Rev. 06/14

Principal Display Panel

NDC 68047-051-10
Oto-End 10
10 mL bottle label

Oto End 10
pramoxine hcl / hydrocortisone / chloroxylenol solution/ drops
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:68047-051
Route of Administration AURICULAR (OTIC) DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Inactive Ingredients
Ingredient Name Strength
# Item Code Package Description
1 NDC:68047-051-10 1 BOTTLE, DROPPER in 1 PACKAGE
1 10 mL in 1 BOTTLE, DROPPER
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 10/12/2007 09/28/2015
Labeler - Larken Laboratories, Inc. (149484540)
Registrant - Larken Laboratories, Inc. (791043719)
Larken Laboratories, Inc.

More about Oto-End (chloroxylenol / hydrocortisone / pramoxine otic)

Consumer resources

Professional resources

Other brands
Oticin HC, Otirx

Related treatment guides